mutation

Introduction. Acute myeloid leukaemia (AML) is a large group of blood and bone marrow oncological diseases characterised by the accumulation of undifferentiated myeloid lin eage cells in peripheral blood or bone marrow. Approximately one-third of leukaemia cases are AML and almost 40% of deaths due to leukaemia are associated with acute myeloid leukaemia. The most inclusive classification of AML is suggested by The World Health Organisation (WHO), which comprises blast morphology, cytogenetic, molecular genetic variations and immunophenotypic markers.